Transactions
13
Insider / CVS HEALTH Corp
AGUIRRE FERNANDO
Director at CVS HEALTH Corp
- Company
- CVS HEALTH Corp
- First filing on record
- October 2, 2025
- Latest trade on record
- September 30, 2026
- SEC filings
- EDGAR ↗
AGUIRRE FERNANDO, Director at CVS HEALTH Corp, has disclosed 13 transactions in SYF, CVS since October 2, 2025: 0 purchases (0 open-market buys) and 2 sales, worth about $3.6M at the reported prices. The latest was filed October 2, 2026, 2 days after the trade; 1 filing was late against the 2-business-day Form 4 deadline.
Open-market buys
0
Sales
2
Avg. disclosure lag
2.2d
Trading in charts
Trade timeline
When does this person trade, how big, and in which direction? Every trade in the last 12 months.
Bought (above the line)Sold (below the line)Other transaction
In the last 12 months AGUIRRE FERNANDO made no purchases and 2 sales worth $3.0M, plus 10 other transactions. Dot size is the dollar amount.
Portfolio mix
Which stocks does this person trade most? Tile size is dollars traded, all time on record.
AGUIRRE FERNANDO has traded 1 stock on record; the largest by dollars is CVS.
Reporting lag
Does this person report on time? One bar per filing against the Form 4 deadline.
On timeLate
1 of 12 filings on record were reported after the Form 4 deadline (two business days, counted here as 4 calendar days).
What kind of transactions
Most Form 4 rows are pay arriving or tax being withheld, not a decision to buy or sell. Only code P is an open-market purchase and code S an open-market sale. What each code means: Form 4 transaction codes.
| Code | Meaning | Rows | Shares | Value |
|---|---|---|---|---|
| A | Grant or award | 11 | 7,373 | $583K |
| D | Sale back to the company | 2 | 32,000 | $3.0M |
| Year | Rows | Bought | Sold |
|---|---|---|---|
| 2026 | 9 | 0 | 2 · $3.0M |
| 2025 | 4 | 0 | 0 |
Transactions
| Security | Side | Trade date | Disclosed | Lag | Shares | Price | Value | Flags | Source | Share |
|---|---|---|---|---|---|---|---|---|---|---|
| SYF | Other A | September 30, 2026 | October 2, 2026 | 2d | 846 | $71 | $60K | Form 4 ↗ | ||
| SYF | Other A | August 17, 2026 | August 19, 2026 | 2d | 14 | $81 | $1,131 | Form 4 ↗ | ||
| SYF | Other A | June 30, 2026 | July 2, 2026 | 2d | 789 | $76 | $60K | Form 4 ↗ | ||
| CVS | Sell D | May 21, 2026 | May 22, 2026 | 1d | 1,563 | $94 | $146K | Form 4 ↗ | ||
| CVS | Sell D | May 20, 2026 | May 22, 2026 | 2d | 30,437 | $94 | $2.9M | Form 4 ↗ | ||
| SYF | Other A | May 15, 2026 | May 19, 2026 | 4d | 14 | $71 | $999 | Form 4 ↗ | ||
| CVS | Other A | May 14, 2026 | May 15, 2026 | 1d | 1,563 | $97 | $152K | Form 4 ↗ | ||
| SYF | Other A | March 31, 2026 | April 2, 2026 | 2d | 883 | $68 | $60K | Form 4 ↗ | ||
| SYF | Other A | February 17, 2026 | February 19, 2026 | 2d | 14 | $72 | $1,012 | Form 4 ↗ | ||
| SYF | Other A | December 31, 2025 | January 5, 2026 | 5d | 660 | $83 | $55K | late | Form 4 ↗ | |
| CVS | Other A | November 20, 2025 | November 21, 2025 | 1d | 1,800 | $76 | $137K | Form 4 ↗ | ||
| SYF | Other A | November 17, 2025 | November 19, 2025 | 2d | 15 | $70 | $1,057 | Form 4 ↗ | ||
| SYF | Other A | September 30, 2025 | October 2, 2025 | 2d | 775 | $71 | $55K | Form 4 ↗ |
Filings
| Filed | Form | Accession | Rows | Status | Source |
|---|---|---|---|---|---|
| October 2, 2026 | Form 4 | 0001224983-26-000011 | 1 | published | EDGAR ↗ |
| August 19, 2026 | Form 4 | 0001224983-26-000010 | 1 | published | EDGAR ↗ |
| July 2, 2026 | Form 4 | 0001224983-26-000008 | 1 | published | EDGAR ↗ |
| May 22, 2026 | Form 4 | 0000064803-26-000084 | 2 | published | EDGAR ↗ |
| May 19, 2026 | Form 4 | 0001224983-26-000005 | 1 | published | EDGAR ↗ |
| May 15, 2026 | Form 4 | 0000064803-26-000076 | 1 | published | EDGAR ↗ |
| April 2, 2026 | Form 4 | 0001224983-26-000003 | 1 | published | EDGAR ↗ |
| February 19, 2026 | Form 4 | 0001224983-26-000002 | 1 | published | EDGAR ↗ |
| January 5, 2026 | Form 4 | 0001224983-26-000001 | 1 | published | EDGAR ↗ |
| November 21, 2025 | Form 4 | 0000064803-25-000057 | 1 | published | EDGAR ↗ |
| November 19, 2025 | Form 4 | 0001224983-25-000006 | 1 | published | EDGAR ↗ |
| October 2, 2025 | Form 4 | 0001224983-25-000004 | 1 | published | EDGAR ↗ |
Other insiders at CVS HEALTH Corp
- Mahoney Michael F Chairman, President & CEO 30 rows
- Casellas Alberto See remarks 23 rows
- KIRBY J SCOTT Director 20 rows
- Finucane Anne A. Director 18 rows
- DOUBLES BRIAN D See remarks 16 rows
- MOTHNER JONATHAN S See remarks 16 rows
- COVIELLO ARTHUR W JR Director 15 rows
- Howse Curtis See remarks 14 rows
- Owens Darrell See remarks 14 rows
- Zane Ellen M Director 14 rows
Everyone on file, with contracts and lobbying under the company's name: CVS HEALTH Corp.
Guides for this page
- What is SEC Form 4? Who files: officers, directors and owners of more than 10% of a class of the company's shares.
- Form 4 transaction codes P = purchase. S = sale. These are the two market trades.
- Insider buying vs insider selling Selling outweighs buying by a wide margin in normal times.
- What disclosure data cannot tell you Filings are late by design: up to 45 days for Congress, two business days for insiders.
Sources and method
| Source | Filings | Rows | First filed | Newest filed | Read the originals |
|---|---|---|---|---|---|
| SEC EDGAR, Form 4 | 12 | 13 | October 2, 2025 | October 2, 2026 | Form 4 list on EDGAR |
Site built October 22, 2026. Every row in the tables above links to its own filing. To quote a figure, use the Cite button at the top of the page; see how to cite and reuse.
Every row comes from the reporting owner's Form 4 as filed with the SEC (EDGAR ownership XML), read daily. "Value" is shares × the reported price; code P is an open-market purchase, S a sale, M an option exercise, A a grant. The lag is the filing date minus the trade date; Form 4 is due within two business days. Amendments (4/A) are not merged. Details on the methodology page; report an error on corrections.
Not investment advice. Figures are public disclosures shown as filed; they may lag the trade and may be amended later. No recommendation is made or implied.